Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.
T Ebata, S Hirano, M Konishi...
https://pubmed.ncbi.nlm.nih.gov/29405274/Actively Recruiting
Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2026-02-09
62
Participants Needed
1
Research Sites
47 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of combining a PD-1 antibody with GEMOX chemotherapy as a postoperative treatment for patients with perihilar cholangiocarcinoma who have cancer spread to their lymph nodes. This exploratory, open-label study seeks to find better options for patients whose prognosis is poorer due to lymph node metastasis after surgery. Participants receive PD-1 antibody infusions and GEMOX chemotherapy, which includes gemcitabine and oxaliplatin. Treatments are given intravenously in cycles lasting three weeks each, with a total of 6 to 8 cycles planned. This combined therapy is given after surgery to assess its potential as an adjuvant treatment. During the study, participants will be closely monitored for disease recurrence and survival, with the main outcome being the relapse-free survival rate at 12 months. Additional assessments include overall survival rates, adverse events, and organ function tests. The study will last several years, including follow-up for up to 60 months to gather long-term data on treatment effects and safety.
CONDITIONS
PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma
R
Rui Zhang, PhD
Y
Yanfang Ye
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 to 8 courses of treatment, each course lasting 3 weeks
Participants receive PD-1 antibody plus GEMOX chemotherapy as postoperative adjuvant therapy following surgery for perihilar cholangiocarcinoma with lymph node metastasis.
Visits on Day 1 and Day 8 of each 3-week course, for up to 8 courses
Duration - Up to 60 months
Participants are followed to monitor relapse-free survival and overall survival after completing adjuvant therapy.
Visits scheduled periodically over 60 months after treatment completion
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Have more questions? Get in touch with our team for quick support
T Ebata, S Hirano, M Konishi...
https://pubmed.ncbi.nlm.nih.gov/29405274/Xiaofeng Chen, Xiaofeng Wu, Hao Wu...
https://pubmed.ncbi.nlm.nih.gov/33172881/Osamu Itano, Yusuke Takemura, Norihiro Kishida...
https://pubmed.ncbi.nlm.nih.gov/32703191/Jesus M Banales, Jose J G Marin, Angela Lamarca...
https://pubmed.ncbi.nlm.nih.gov/32606456/Makoto Ueno, Masafumi Ikeda, Chigusa Morizane...
https://pubmed.ncbi.nlm.nih.gov/31109808/Koichi Nakahashi, Tomoki Ebata, Yukihiro Yokoyama...
https://pubmed.ncbi.nlm.nih.gov/32665142/Bas Groot Koerkamp, Jimme K Wiggers, Peter J Allen...
https://pubmed.ncbi.nlm.nih.gov/26454735/Julien Edeline, Meher Benabdelghani, Aurélie Bertaut...
https://pubmed.ncbi.nlm.nih.gov/30707660/John N Primrose, Richard P Fox, Daniel H Palmer...
https://pubmed.ncbi.nlm.nih.gov/30922733/Ibrahim Nassour, Ali A Mokdad, Matthew R Porembka...
https://pubmed.ncbi.nlm.nih.gov/29488187/Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead Sponsor